Is SpyGlass Pharma, Inc. Common Stock (SGP) a Buy, Sell, or Hold?
NASDAQ : SGP
SpyGlass Pharma, Inc. Common Stock
$20.49 USD
-$0.39 (-1.87%)
- Volume
- 103.82K
- Average Volume
- 110.5K
- Market Capitalization
- $685.05M
- P/E Ratio
- -19.15
- Dividend Yield
- 0.00%
- Price Target
- $62.00
- Year High
- $32.44
- Year Low
- $17.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $38.00
Company Overview
NASDAQ
Patrick H. Mooney
Biotechnology
Healthcare
SGP
65
US
USD
Liquidity Metrics
0.01
38.00
38.00
35.83
0.00
Sales & Valuation
-$
0.00
1.63
-28.57
-1.20
Profitability
-$1.19
-$39.87M
0.00%
0.00%
-123.53%
-10.21%
P/E Metrics
-19.15
-0.19
-0.19
Analyst Price Target & Rating
$62.00
$62.00
$62.00
2/5
0 Analysts
-66.95%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
$447.75M
0.00
-17.33
38.00
-123.53%
-11.54%
-6.46%
-3.50%
-2399 days
Company Executives
| Name | Title |
|---|---|
| Shannon Trevino | General Counsel |
| Chetan Pujara | Chief Research & Development Officer |
| Glenn Sussman | Co-founder & Chief Technology Advisor |
| James Robert Dennewill Jr. | Chief Operating Officer |
| Patrick H. Mooney | CEO & Director |
| Nina Nguyen | Senior Vice President, Regulatory & Quality |
| Rachel Gilette | Vice President of Human Resources |
| Long Doan | VP & Head of Clinical Operations |
| Jean-Frederic Viret | Chief Financial Officer |
| Malik Y. Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman |
| Paul Yoo | Senior Vice President of Clinical Development |
Poll Results
No votes yet today — be the first to share your view!
About SpyGlass Pharma, Inc. Common Stock (NASDAQ:SGP) Stock
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA. ...
Spyglass Pharma (NASDAQ:SGP) Shares Gap Up – Still a Buy?
2026-07-26 02:02:41
Spyglass Pharma, Inc. (NASDAQ: SGP - Get Free Report)'s stock price gapped up prior to trading on Friday. The stock had previously closed at $20.88, but opened at $21.80. Spyglass Pharma shares last traded at $21.2550, with a volume of 12,107 shares. Analyst Ratings Changes Separately, Wall Street Zen lowered Spyglass Pharma from a "hold"
Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGP
2026-07-25 04:43:30
Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma, Inc. (NASDAQ: SGP) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 250,000 shares of the company's stock, valued at approximately $6,478,000. Affinity Asset Advisors LLC owned about
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
2026-06-15 08:00:00
ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
2026-06-02 08:00:00
ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing.
SpyGlass Pharma to Participate in Upcoming Investor Conferences
2026-05-21 08:00:00
ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026Time: 2:00 p.m.
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
2026-05-18 08:00:00
ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new add-on Category III CPT code for attachment and insertion of intraocular lens prosthesis-mounted drug-eluting implant, based on the application submitted for the Bimatoprost Drug Pad-IOL System (BIM-IOL System), in conjunction with established Category I cataract surgery procedure codes.
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-14 16:05:00
ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the first quarter ended March 31, 2026.
Frequently Asked Questions
-
What is the current SpyGlass Pharma, Inc. Common Stock (SGP) stock price?
-
SpyGlass Pharma, Inc. Common Stock(NASDAQ:SGP) stock price is $20.49 in the last trading session. During the trading session, SGP stock reached the peak price of $32.44 while $17.06 was the lowest point it dropped to. The percentage change in SGP stock occurred in the recent session was --1.87% while the dollar amount for the price change in SGP stock was -$0.39.
-
SGP's industry and sector of operation?
-
The NASDAQ listed SGP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SGP?
-
Shannon Trevino | General Counsel
Chetan Pujara | Chief Research & Development Officer
Glenn Sussman | Co-founder & Chief Technology Advisor
James Robert Dennewill Jr. | Chief Operating Officer
Patrick H. Mooney | CEO & Director -
How many employees does SGP have?
-
Number of SGP employees currently stands at 65. SGP operates from 27061 Aliso Creek Road, Aliso Viejo, CA 92656, US.
-
Link for SGP official website?
-
Official Website of SGP is: http://www.spyglasspharma.com
-
How do I contact SGP?
-
SGP could be contacted at phone #1 949 535 0588 and can also be accessed through its website. SGP operates from 27061 Aliso Creek Road, Aliso Viejo, CA 92656, US.
-
How many shares of SGP are traded daily?
-
The average number of SGP shares traded daily for last 3 months was 110.5K.
-
What is the market cap of SGP currently?
-
The market value of SGP currently stands at $685.05M with its latest stock price at $20.49